[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,431,758
  • Shares Outstanding, K 797,750
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,080 M
  • EBIT $ -869 M
  • EBITDA $ -869 M
  • 60-Month Beta -1.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 16.92

Options Overview Details

View History
  • Implied Volatility 99.23% (+6.81%)
  • Historical Volatility 69.48%
  • IV Percentile 55%
  • IV Rank 33.18%
  • IV High 183.25% on 01/27/26
  • IV Low 57.51% on 01/21/26
  • Expected Move (DTE 7) 1.11 (8.02%)
  • Put/Call Vol Ratio 0.48
  • Today's Volume 745
  • Volume Avg (30-Day) 6,015
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 154,230
  • Open Int (30-Day) 135,461
  • Expected Range 12.68 to 14.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.28
  • Number of Estimates 3
  • High Estimate $-0.27
  • Low Estimate $-0.29
  • Prior Year $-0.31
  • Growth Rate Est. (year over year) +9.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.07 +13.50%
on 08/17/26
15.75 -13.02%
on 08/12/26
+1.15 (+9.16%)
since 07/28/26
3-Month
12.07 +13.50%
on 08/17/26
18.50 -25.97%
on 05/29/26
-3.71 (-21.31%)
since 05/28/26
52-Week
12.07 +13.50%
on 08/17/26
29.23 -53.13%
on 04/21/26
-10.72 (-43.90%)
since 08/28/25

Most Recent Stories

More News
Stocks Finish Little Changed Ahead of Nvidia Earnings

The S&P 500 Index ($SPX ) (SPY ) closed down by -0.02% on Wednesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.05%....

INTU : 353.54 (+1.59%)
$SPX : 7,763.23 (+0.42%)
BSX : 46.74 (+0.15%)
SMMT : 13.64 (-4.82%)
DDOG : 241.44 (-0.61%)
ORCL : 152.16 (+0.14%)
NKE : 39.25 (+2.11%)
$IUXX : 29,711.33 (+0.24%)
NQU26 : 29,795.25 (+0.34%)
WMB : 74.23 (+0.05%)
SMTC : 135.27 (-5.03%)
QQQ : 722.89 (+0.25%)
Stocks Slip Ahead of Nvidia Earnings as Bond Yields Rise

The S&P 500 Index ($SPX ) (SPY ) is down by -0.02% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.10%. E-mini S&P futures...

INTU : 353.54 (+1.59%)
DDOG : 241.44 (-0.61%)
$IUXX : 29,711.33 (+0.24%)
ZNZ26 : 108-080 (-0.07%)
GDDY : 96.66 (-0.33%)
ESU26 : 7,779.00 (+0.47%)
SJM : 132.44 (+0.46%)
$DOWI : 53,758.34 (+0.35%)
LPLA : 367.30 (+1.68%)
SPY : 774.22 (+0.40%)
DIA : 536.79 (+0.29%)
$SPX : 7,763.23 (+0.42%)
Stocks Slightly Higher on Mixed US Economic News

The S&P 500 Index ($SPX ) (SPY ) is up by +0.04% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.01%. E-mini S&P futures (ESU26...

INTU : 353.54 (+1.59%)
$SPX : 7,763.23 (+0.42%)
BSX : 46.74 (+0.15%)
SMMT : 13.64 (-4.82%)
DDOG : 241.44 (-0.61%)
ORCL : 152.16 (+0.14%)
KSS : 17.98 (-0.94%)
$IUXX : 29,711.33 (+0.24%)
NQU26 : 29,795.25 (+0.34%)
SMTC : 135.27 (-5.03%)
QQQ : 722.89 (+0.25%)
CLV26 : 82.89 (-0.77%)
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

HARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS Superiority vs. Anti-PD-(L)1 Plus Chemotherapy First Phase III...

SMMT : 13.64 (-4.82%)
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology

First Immunotherapy-Based Regimen to Show Statistically Significant and Clinically Meaningful PFS Benefit in a Global Phase III Study of EGFR-Mutated NSCLC after Third-Generation EGFR TKI Progression ...

SMMT : 13.64 (-4.82%)
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

Marks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China   ...

SMMT : 13.64 (-4.82%)
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer

HARMONi-GU1 Is First Global Registrational Clinical Trial of Ivonescimab in a Genitourinary (GU) Cancer, Adding to Global Phase III Ivonescimab Studies in NSCLC and CRC ...

SMMT : 13.64 (-4.82%)
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm

NEW YORK , July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT)...

SMMT : 13.64 (-4.82%)
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy ...

SMMT : 13.64 (-4.82%)
Summit Therapeutics: The Conference Call Scheduled After Tomorrow's Close

Barchart Research What to Expect from SMMT Earnings SMMT Generated July 22, 2026 Current Price $14.74 EPS Estimate $$-0.26 Consensus Rating Moderate Buy Average Move 7.42% Summit Therapeutics: The Conference...

SMMT : 13.64 (-4.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 15.41
2nd Resistance Point 15.03
1st Resistance Point 14.68
Last Price 13.64
1st Support Level 13.95
2nd Support Level 13.57
3rd Support Level 13.22

See More

52-Week High 29.23
Fibonacci 61.8% 22.67
Fibonacci 50% 20.65
Fibonacci 38.2% 18.63
Last Price 13.64
52-Week Low 12.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.